Labopharm grants tramadol analgesic distribution rights in Mexico to Glaxo Group

By Angela McDaniels

Seattle, May 31 - Labopharm Inc. has granted Glaxo Group Ltd. exclusive rights to distribute its once-daily analgesic tramadol in Mexico, according to a company news release.

In addition to specified milestone payments, Labopharm will receive a percentage of once-daily tramadol net sales in Mexico, resulting in an effective royalty rate similar to those of the company's U.S. and European partnerships.

This agreement expands the existing licensing and distribution arrangement for 20 Latin American and Caribbean countries the two companies entered into in September 2005.

"Having already received regulatory approval for Mexico, we will work with Glaxo Group to launch our product as rapidly as possible in that country," Labopharm president and chief executive officer James R. Howard-Tripp said in the release.

The company said tramadol products are currently available in Mexico only in immediate-release (four- to six-times daily) formulations and twice-daily formulations.

Labopharm is a specialty pharmaceutical company based in Laval, Quebec, that develops drugs incorporating Contramid, its proprietary controlled-release technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.